-
The Safety of Methyl 1-(2,3-dihydroxypropyl)-1,4-dihydro-4-oxo-3-(phenylmethoxy)-2-pyridinecarboxylate
Time of Update: 2023-05-17
Workers who handle the compound should be protected with appropriate gear and training, and proper safety measures should be established to prevent accidents and mitigate the potential health risks associated with it.
-
Preclinical studies have identified potential treatments for metastatic colon cancer
Time of Update: 2022-12-30
Hirst III professors of oncology pathology at Weill Cornell Medical College, in a study published Dec. 15 in Cancer Cells found that the accumulation of a molecule called hyaluronic acid is a key step in the formation of mCRC tumors.
-
"Lancet" sub-issue: domestic bivalent HPV vaccine can be fought! The results of the first domestic divalent HPV vaccine 5.5 years follow-up were released, the protection rate was 100
Time of Update: 2022-09-21
Overall, the 5-and-a-half-year follow-up results confirmed that the first domestic bivalent HPV vaccine was effective and safe, and could be used to prevent HPV16/18-related precancerous lesions and persistent infections in women aged 18-45 years.
-
"Hard-to-talk" cancer: an emerging standard for rare diseases
Time of Update: 2022-09-15
Studies have shown that the objective response rate (ORR) of treating refractory SCCA with navulijumab monotherapy was 24%, with 2 patients achieving complete remission and 7 patients achieving partial remission, median progression-free survival (PFS) of 4.
-
Chin J Cancer Res: Phase III study by Prof. Baohui Han's team shows that QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer
Time of Update: 2022-04-22
Recently, the Chinese Journal of Cancer Research published a 2-year follow-up update of a study by Professor Han Baohui's team from Shanghai Chest Hospital, which mainly evaluated the comparison of bevacizumab biosimilar QL1101 with bevacizumab in the treatment of non-patients.
-
Prof. Tao Wang: New research on new drugs has come out, consolidating the evidence of evidence-based medicine, and reviewing and prospecting the progress of adjuvant therapy for breast cancer
Time of Update: 2022-01-24
The Monarch E study showed that the addition of a "targeted drug" CDK4/6 inhibitor (abecili) on the basis of the original standard endocrine therapy in high-risk HR-positive breast cancer patients can improve disease-free survival (DFS) and long-term maintain efficacy .
-
Ann Surg: Recurrent laryngeal nerve monitoring can improve the effect of lymph node dissection during esophageal cancer resection
Time of Update: 2021-08-13
The occurrence of the primary tumor site and depth of invasion, metastasis incidence RLN esophageal squamous cell carcinoma (ESCC) fluctuations in 8.
Improving Outcome of Superior Mediastinal Lymph Node Dissection During Esophagectomy: A Novel Approach Combining Continuous and Intermittent Recurrent Laryngeal Nerve Monitoring .
-
Nat Commun: Phase Ib clinical results of inositol triphosphate treatment for patients with hepatobiliary tumors announced
Time of Update: 2021-08-01
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
Nature Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
-
How do Qilu and Yilian Biopharmaceuticals add next-generation ADC drugs
Time of Update: 2021-07-28
03 Conversion of IgG4 to IgG1 The first-generation ADC drug Mylotarg uses IgG4 as an antibody, but IgG4 molecules cannot cause Fc-mediated ADCC, CDC and ADCP effects.
With this technology, ADC drugs with a DAR of 10-12 can be designed, laying the foundation for the use of lower-toxic payloads .
-
How to treat malignant gastrointestinal obstruction
Time of Update: 2021-04-19
Best practice recommendation 8: For patients with gastric outlet obstruction who are not suitable for gastrojejunostomy (surgical operation or endoscopic ultrasound guidance), clinicians should consider intestinal stent placement.
-
"Bladder" no longer ASCO-GU: immunotherapy strongly breaks through the difficulties of bladder cancer assistance, DFS will eventually double
Time of Update: 2021-03-22
"CheckMate-274 is the first and currently the only phase III clinical study that confirmed immunotherapy as an adjuvant treatment for myometrial invasive urothelial carcinoma, and achieved positive results in all random populations and those with PD-L1 expression ≥1%.
-
Watch out! Guizhou notified 20 batches of unqualified food, involving beverages, edible agricultural products
Time of Update: 2020-12-06
"National Standard for Food Safety Packaging Drinking Water" (GB 19298-2014) stipulates that the copper-green fake monocytobacteria in packed drinking water shall not be detected in 5 test results.
-
Biochem Pharmacol: Experimental drugs have the potential to treat new coronavirus infections
Time of Update: 2020-10-06
the team must develop a clinical trial plan and obtain FDA approval to test AR-12 on COVID-19 patients and manufacture enough drugs to be tested.
-
Molecular Cell: DNA damage promotes the degradation of TMPRSS2-ERG cancer proteins and inhibits prostate cancer progression
Time of Update: 2020-09-23
the elimination of the cancer-related gene PTEN or infergic GSK3 beta eliminates the degradation of TMPRSS2-ERG induced by DNA damage.
blocking the DNA damage-induced degradation process of TMPRSS2-ERG cancer proteins in fusion protein-positive PCa cells and mouse models can cause tumor cells to develop chemotherapy resistance.
-
In June Nature magazine had to look at a study of the heavyweight highlights
Time of Update: 2020-08-01
On May 26, Nature magazine published two new studies by Chinese scientists that isolated SARS-CoV-2-specific high-active neutral antibodies from patients.
For the study, the researchers reported the separation and identification of 206 RBD-specific monoclonal antibodies from a single B cell in eight SARS-CoV-2 infected people.
